NeonMind Biosciences Inc (TSE:LCR)
:LCR
Want to see TSE:LCR full AI Analyst Report?
LCR Stock Chart & Stats
C$0.04
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.04
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.08
Previous CloseN/A
Volume126.00K
Average Volume (3M)290.69K
Market Cap
C$3.24M
Enterprise ValueC$3.34M
Total Cash (Recent Filing)C$206.03K
Total Debt (Recent Filing)C$1.14M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding92,499,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Psilocybin R&DNeonMind’s explicit strategic focus on psilocybin-based mental-health therapeutics establishes a durable product roadmap addressing large, structurally underserved psychiatric markets. Specialization improves ability to attract targeted partners, grants, and licensing opportunities versus a generalist biotech approach.
Improving Cash-flow TrendReported improvement in free cash flow versus the prior year signals operational progress and early efficiency gains. A sustained improvement trend can extend runway, reduce near-term financing reliance, and indicate management is tightening spend or advancing programs more cost-effectively.
Moderate Absolute Debt LevelsAbsolute debt of roughly $1.1–$1.2M is moderate for an early-stage biotech and limits fixed financing burden. Lower nominal leverage provides flexibility to prioritize R&D or negotiate non-dilutive funding, assuming equity or partnership capital remains accessible to support clinical progression.
Bears Say
No Meaningful RevenueThe absence of recurring or meaningful revenue across multiple years leaves the business entirely reliant on external funding, partnerships, or milestone/license deals. This lack of revenue undermines self-funding capacity and makes the firm dependent on capital markets or strategic counterparties.
Persistent Negative Cash FlowSustained negative operating cash flow and ongoing cash burn materially increase funding needs. Continued deficits pressure liquidity, raise dilution risk from future financing, and constrain the company’s ability to scale trials or commercialization without secure external capital or partner commitments.
Negative Shareholders' EquityNegative shareholders’ equity signals prolonged losses and solvency strain, weakening financial flexibility. This condition can limit borrowing capacity, raise counterparty concerns, and increase probability of dilutive recapitalizations or restructuring if operating losses continue.
NeonMind Biosciences Inc News
LCR FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was C$0.03 and its highest was C$0.08 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is C$3.24M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Aug 05, 2026 which is in 58 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
NeonMind Biosciences Inc released its earnings results on Mar 03, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 92,499,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
NeonMind Biosciences Inc reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:LCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. focuses on acquiring, exploring, and advancing both mineral deposits and sustainable energy initiatives. A notable asset for the company is its exclusive right to acquire full ownership of the Alkali Flat lithium brine project, located in Lordsburg, New Mexico, in the United States. The firm's headquarters are situated in West Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---